BioMarin Pharmaceutical (NASDAQ:BMRN) is set to announce its earnings results after the market closes on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.
BioMarin Pharmaceutical (BMRN) opened at $84.98 on Tuesday. The stock has a market cap of $14,920.00, a P/E ratio of -102.39 and a beta of 1.71. BioMarin Pharmaceutical has a fifty-two week low of $78.50 and a fifty-two week high of $100.51. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41.
A number of research analysts recently issued reports on BMRN shares. Stifel Nicolaus dropped their price objective on shares of BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating for the company in a report on Friday, October 27th. BMO Capital Markets raised their price objective on shares of BioMarin Pharmaceutical from $117.00 to $119.00 and gave the company an “outperform” rating in a report on Friday, October 27th. JPMorgan Chase & Co. set a $130.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Sunday, October 29th. Wedbush reiterated a “neutral” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a report on Wednesday, November 15th. Finally, SunTrust Banks raised their price objective on shares of BioMarin Pharmaceutical to $130.00 and gave the company a “buy” rating in a report on Monday, December 11th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. BioMarin Pharmaceutical has an average rating of “Buy” and an average target price of $111.60.
In other BioMarin Pharmaceutical news, Director Elaine J. Heron sold 800 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $88.90, for a total transaction of $71,120.00. Following the completion of the transaction, the director now owns 38,385 shares in the company, valued at approximately $3,412,426.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP George Eric Davis sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $90.66, for a total transaction of $2,719,800.00. Following the transaction, the executive vice president now owns 112,942 shares of the company’s stock, valued at approximately $10,239,321.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,750 shares of company stock valued at $8,159,588. Company insiders own 1.85% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BioMarin Pharmaceutical (BMRN) Set to Announce Earnings on Thursday” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/20/biomarin-pharmaceutical-bmrn-set-to-announce-earnings-on-thursday.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.